Access Erosion & Value Signals

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics feel particularly urgent for understanding system sustainability.

MarcusSame here. We're looking at HCA's profit warning signals of access erosion — why that matters for commercial viability. Then subcutaneous Leqembi reshaping Alzheimer's value narratives. The FTC-CVS insulin settlement exposing PBM practices. And ICER's early-phase scientific advice expansion.

SaraThat second one hits hard — the budget impact question for Alzheimer's therapies is one the field hasn't fully worked out yet.

MarcusExactly. Let's get into it.

MarcusStarting with HCA's profit warning. This isn't just a financial alert; it's a symptom of broader access erosion. When major hospital systems flag profitability concerns, it cascades through provider networks. The pressure on reimbursement pathways intensifies.

SaraAbsolutely. What strikes me is how this connects to payer formulary decisions. When systems struggle financially, they become less willing to absorb high-cost innovations, regardless of clinical value. The budget impact equation shifts dramatically.

MarcusThat's fair, though I think we'd see similar access concerns even in financially stable systems. The underlying tension is between innovation investment and system-wide cost containment.

SaraThe part that gives me pause is the precedent this sets. If HCA's signals lead to more restrictive coverage policies, it could trigger a domino effect across other health systems. Payers will point to these warnings as justification for stricter prior authorization.

MarcusI wonder if that's the full picture though. These warnings also highlight the need for more differentiated value evidence. If therapies can't demonstrate clear cost offsets beyond the direct treatment, they face an uphill battle.

SaraRight, and from the payer side, the opportunity cost argument becomes unavoidable. Every dollar spent on one high-cost therapy is a dollar not spent on other interventions. That's the reality HCA's warning underscores.

MarcusThis is one of those stories where the commercial and patient access interests collide. We need evidence that speaks to both value and sustainability.

SaraNow, subcutaneous Leqembi. This formulation change is significant beyond just administration convenience. It fundamentally changes the value proposition for Alzheimer's treatments.

MarcusExactly. The reduced burden on caregivers could translate to lower indirect costs in real-world settings. But I'm curious how HTA bodies will capture that in their assessments.

SaraThat's one read — I'd frame it slightly differently. The key question is whether payers will recognize the caregiver burden reduction as a cost offset. Most HTA frameworks still struggle with quantifying indirect benefits.

MarcusWhat strikes me is how this connects to the broader Alzheimer's value narrative. With multiple agents entering the market, the evidence bar for differentiation is rising rapidly. Real-world data on treatment adherence and caregiver impact will become critical.

SaraThe part that gives me pause is the precedent for subcutaneous biologics in neurodegenerative diseases. If Leqembi succeeds here, it could open pathways for other high-cost therapies. That's a budget impact concern we haven't fully modeled.

MarcusI'd push back slightly on that. The success here depends entirely on demonstrating incremental value over existing options. It's not about the route of administration but the overall benefit-risk profile.

SaraFair point, though I think payers would see it differently. The administration cost savings are real but may not offset the drug's price premium. That's the tension we'll see in coverage decisions.

MarcusThis is genuinely one of the most watched value stories in neurology. How they handle this will shape future HTA approaches for chronic progressive diseases.

MarcusMoving to the FTC-CVS insulin settlement. This isn't just about one company; it's a fundamental challenge to pharmacy benefit manager practices. The settlement exposes the hidden costs embedded in PBM operations.

SaraWhat strikes me is how this connects to broader insulin access issues. When rebates and fees aren't transparent, the actual cost burden on payers and patients becomes obscured. That distorts the entire value conversation.

MarcusExactly. The settlement forces a reckoning with how we assess value in the insulin market. If rebates aren't passed through to patients, the list price becomes meaningless as a value signal.

SaraThat's one read — I'd frame it slightly differently. The real issue is the structural misalignment between manufacturer pricing and patient out-of-pocket costs. Until that's addressed, value assessments remain incomplete.

MarcusI wonder if that's the full picture though. This could also signal a shift toward more competitive insulin pricing. If transparency increases, we might see price competition based on actual value rather than rebate structures.

SaraThe part that gives me pause is the precedent for other therapeutic areas. If this settlement leads to more aggressive FTC scrutiny of PBM practices, it could reshape how manufacturers approach value-based pricing across the board.

MarcusThis is genuinely a watershed moment for drug pricing transparency. How it plays out will determine whether value assessments can finally move beyond list price considerations.

SaraFinally, ICER's early-phase scientific advice expansion. This is a significant evolution in how we approach evidence generation, particularly for innovative therapies.

MarcusAbsolutely. By engaging earlier, companies can design trials that generate evidence more aligned with HTA requirements. It's about de-risking the development pathway.

SaraThat's fair, though I think we need to be careful about expectations. Early advice doesn't guarantee favorable outcomes. The evidence standards remain rigorous, regardless of when the engagement occurs.

MarcusWhat strikes me is how this connects to the broader trend of adaptive licensing frameworks. Early scientific advice could become a cornerstone of those approaches, allowing for more flexible evidence generation.

SaraThe part that gives me pause is the resource implications. If HTA bodies expand their early-phase services, will that strain their capacity? We've seen similar challenges with JCA scientific advice slots.

MarcusI'd push back slightly on that. The alternative is generating evidence that doesn't meet payer requirements, which wastes even more resources. This is about smarter evidence generation from the start.

SaraThat's one read — I'd frame it slightly differently. The real opportunity is in aligning R&D investment with market access needs earlier. It could reduce the late-stage attrition we often see.

MarcusThis is genuinely a game-changer for HEOR strategy. Companies that embrace this approach will have a significant advantage in demonstrating value.

SaraA lot to think about today. I'll be watching how HCA's signals translate to coverage policies and whether we see broader formulary restrictions follow.

MarcusSame — and for me the thread running through today is the tension between innovation investment and system sustainability. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.